Final Results (part 2 of 2)
AstraZeneca PLC
30 January 2003
Consolidated Profit & Loss Account For Continuing Operations
2002 2001
For the year ended 31 December $m (Restated)
$m
Sales 17,841 16,222
Cost of sales (4,520) (4,198)
Distribution costs (141) (122)
Research and development (3,069) (2,687)
Selling, general and administrative expenses (5,998) (5,427)
Other operating income 243 368
Operating profit before exceptional items 4,356 4,156
Exceptional items charged to operating profit (350) (202)
Operating profit 4,006 3,954
Share of joint ventures' and associates' operating profits - -
Profit on sale of fixed assets - 10
Net interest and dividend income 31 113
Profit on ordinary activities before taxation 4,037 4,077
Profit before taxation before exceptional items 4,387 4,269
Exceptional items charged to profit before taxation (350) (192)
Taxation (1,177) (1,160)
Profit on ordinary activities after taxation 2,860 2,917
Attributable to minorities (24) (11)
Net profit for the year 2,836 2,906
Dividends to Shareholders (1,206) (1,225)
Earnings per Ordinary Share before exceptional items $1.84 $1.73
Earnings per Ordinary Share $1.64 $1.65
Diluted earnings per Ordinary Share $1.64 $1.65
Weighted average number of Ordinary Shares in issue (millions) 1,733 1,758
Diluted average number of Ordinary Shares in issue (millions) 1,735 1,761
Consolidated Profit & Loss Account For Continuing Operations
2002 2001
For the quarter ended 31 December $m (Restated)
$m
Sales 4,901 4,366
Cost of sales (1,253) (1,132)
Distribution costs (39) (33)
Research and development (892) (732)
Selling, general and administrative expenses (1,661) (1,443)
Other operating income 18 64
Operating profit before exceptional items 1,074 1,090
Exceptional items charged to operating profit (350) (76)
Operating profit 724 1,014
Share of joint ventures' and associates' operating profits - -
Profit on sale of fixed assets - -
Net interest and dividend income 7 12
Profit on ordinary activities before taxation 731 1,026
Profit before taxation before exceptional items 1,081 1,102
Exceptional items charged to profit before taxation (350) (76)
Taxation (291) (296)
Profit on ordinary activities after taxation 440 730
Attributable to minorities (12) (4)
Net profit for the period 428 726
Dividends to Shareholders (808) (820)
Earnings per Ordinary Share before exceptional items $0.45 $0.45
Earnings per Ordinary Share $0.25 $0.42
Diluted earnings per Ordinary Share $0.25 $0.42
Weighted average number of Ordinary Shares in issue (millions) 1,723 1,750
Diluted average number of Ordinary Shares in issue (millions) 1,725 1,752
Consolidated Balance Sheet
2002 2001
At 31 December $m (Restated)
$m
Fixed assets
Tangible fixed assets 6,597 5,409
Goodwill and intangible assets 2,807 2,700
Fixed asset investments 46 23
9,450 8,132
Current assets
Stocks 2,593 2,402
Debtors 4,845 4,139
Cash and short-term investments 4,688 3,823
12,126 10,364
Total assets 21,576 18,496
Creditors due within one year
Short-term borrowings and current instalments of loans (516) (321)
Other creditors (7,699) (6,159)
(8,215) (6,480)
Net current assets 3,911 3,884
Total assets less current liabilities 13,361 12,016
Creditors due after more than one year
Loans (328) (635)
Other creditors (34) (152)
Provisions for liabilities and charges (1,773) (1,600)
(2,135) (2,387)
Net assets 11,226 9,629
Capital and reserves
Shareholders' funds - equity interests 11,172 9,586
Minority equity interests 54 43
Shareholders' funds and minority interests 11,226 9,629
Statement of Total Recognised Gains and Losses
2002 2001
For the year ended 31 December $m (Restated)
$m
Net profit for the financial year 2,836 2,906
Exchange adjustments on net assets 1,106 (502)
Translation differences on foreign currency borrowings 6 18
Tax on translation differences on foreign currency borrowings (2) (6)
Total recognised gains and losses for the financial year 3,946 2,416
Prior Year adjustment (FRS 19 Deferred Tax) (200)
Total gains and losses recognised since last Annual Report 3,746
Consolidated Cash Flow Statement
2002 2001
For the year ended 31 December $m $m
Cash flow from operating activities
Operating profit before exceptional items 4,356 4,156
Depreciation and amortisation 960 860
Decrease/(increase) in working capital 305 (1,006)
Other non-cash movements 65 120
Net cash inflow from operating activities before exceptional
items 5,686 4,130
Outflow related to exceptional items (93) (368)
Net cash inflow from operating activities 5,593 3,762
Returns on investments and servicing of finance 35 156
Tax paid (795) (792)
Capital expenditure and financial investment (1,543) (1,543)
Acquisitions and disposals - (44)
Equity dividends paid to Shareholders (1,234) (1,236)
Net cash inflow before management of liquid resources and
financing 2,056 303
Management of liquid resources
Movement in short-term investments and fixed deposits (net) (806) 260
Financing (1,272) (959)
Decrease in cash in the year (22) (396)
Reconciliation of Cash Flow to Net Cash Funds
2002 2001
For the year ended 31 December $m $m
Net funds at 1 January 2,867 3,605
Net cash flows before management of liquid resources and
financing 2,056 303
Net cash flows from share issues and repurchases (1,154) (994)
Exchange 75 (47)
Net funds at 31 December 3,844 2,867
Notes to the Preliminary Announcement
1 BASIS OF PREPARATION AND ACCOUNTING POLICIES
The results for the full year ended 31 December 2002 have been prepared in
accordance with UK generally accepted accounting principles. The accounting
policies applied are those set out in AstraZeneca PLC's 2001 Annual Report and
Form 20-F except that, in the current period, AstraZeneca adopted Financial
Reporting Standard No. 19 'Deferred Tax'. Prior periods have been restated and
the effects of this restatement were to reduce profits for the full year ended
31 December 2001 by $61m and reduce net assets at that date by $193m. The table
below illustrates the effect on EPS before exceptional items of this
restatement.
The results for the year ended 31 December 2002 presented in this preliminary
announcement are extracted from, and are consistent with, those in the Group's
audited financial statements for the year ended 31 December 2002 and those
financial statements will be delivered to the Registrar of Companies following
the Company's Annual General Meeting.
2001 TAXATION AND EARNINGS PER SHARE BEFORE EXCEPTIONAL ITEMS
Q1 2001 Q2 2001 Q3 2001 Q4 2001 Year
Tax charge before adoption of FRS 19 ($m) (316) (269) (286) (282) (1,153)
Tax charge after adoption of FRS 19 ($m) (315) (289) (295) (315) (1,214)
Published EPS before adoption of FRS 19 ($) 0.45 . 0.42 0.43 0.47 1.77
Adjusted EPS after adoption of FRS 19 ($) 0.45 0.41 0.42 0.45 1.73
As part of AstraZeneca's objective to align with accounting best practice, cash
discounts arising from prompt payment of invoices have been reclassified from
cost of sales to sales. Comparatives have also been reclassified for
consistency of presentation. Both sales and cost of sales have been reduced by
$74m in the fourth quarter 2002 and $287m in the current year (2001 $258m, 2000
$221m). Furthermore, neither profits nor net assets have been affected. The
change has minimal impact on previously stated sales growth rates. The
reclassified quarterly sales figures are presented below. Additional detail at
the product and territorial level are available on the AstraZeneca website.
2002 Sales and Cost of Sales reclassified for cash discounts
Q1 2002 Q2 2002 Q3 2002
Sales as previously reported ($m) 4,421 4,382 4,350
Reclassified Sales ($m) 4,346 4,312 4,282
Cost of Sales as previously reported ($m) 1,169 1,130 1,181
Reclassified Cost of Sales ($m) 1,094 1,060 1,113
Operating margin as reported 29.3% 24.3% 21.2%
Adjusted operating margin 29.8% 24.7% 21.5%
2001 Sales and Cost of Sales reclassified for cash discounts
Q1 2001 Q2 2001 Q3 2001 Q4 2001 Year
Sales as previously reported ($m) 3,991 4,099 3,950 4,440 16,480
Reclassified Sales ($m) 3,933 4,035 3,888 4,366 16,222
Cost of Sales as previously reported ($m) 1,074 1,112 1,064 1,206 4,456
Reclassified Cost of Sales ($m) 1,016 1,048 1,002 1,132 4,198
Operating margin as previously reported 26.4% 24.3% 25.7% 24.5% 25.2%
Adjusted operating margin 26.8% 24.7% 26.1% 25.0% 25.6%
Information in this preliminary announcement does not constitute statutory
accounts of the Group within the meaning of Section 240 of the Companies Act
1985. Statutory accounts for the year ended 31 December 2001 have been filed
with the Registrar of Companies. The auditor's report on those accounts was
unqualified and did not contain any statement under Section 237 of the Companies
Act 1985.
2 JOINT VENTURES AND ASSOCIATES
The Group's share of joint ventures' sales for the year ended 31 December 2002
amounted to $191m and $183m for the comparative period. Share of joint
ventures' operating profits for the year ended 31 December 2001 and 2002
amounted to nil.
3 ANALYSIS OF EXCEPTIONAL ITEMS CHARGED TO OPERATING PROFIT
2002 2001
$m $m
Accrual related to Zoladex investigations 350 -
Synergy and integration charge - 202
350 202
4 RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS
2002 2001
For the year ended 31 December $m (Restated)
$m
Shareholders' funds at beginning of year (originally $9,786m
before deducting prior period adjustment of $200m) 9,586 9,382
Net profit for the year 2,836 2,906
Dividends to Shareholders (1,206) (1,225)
1,630 1,681
Issue of AstraZeneca PLC Ordinary Shares 36 86
Repurchase of AstraZeneca PLC Ordinary Shares (1,190) (1,080)
Foreign currency adjustment 1,110 (483)
Net addition to Shareholders' funds 1,586 204
Shareholders' funds at end of year 11,172 9,586
5 NET CASH FUNDS
The table below provides an analysis of net cash funds and a reconciliation of
net cash flow to movement in net cash funds.
At 31 Dec Cash Other Exchange At 31 Dec
2001 flow non-cash movements 2002
$m $m $m $m $m
Loans due after 1 year (635) 28 279 - (328)
Current instalments of loans (107) 77 (279) (5) (314)
Total loans (742) 105 - (5) (642)
Short-term investments 3,118 806 - 38 3,962
Cash 705 (18) - 39 726
Overdrafts (195) (4) - (3) (202)
Short-term borrowings, excluding
overdrafts (19) 13 - 6 -
3,609 797 - 80 4,486
Net cash funds 2,867 902 - 75 3,844
Issue of AstraZeneca PLC Ordinary Shares (36)
Repurchase of AstraZeneca PLC Ordinary
Shares 1,190
Net cash inflow before management of
liquid resources and financing 2,056
6 FULL YEAR TERRITORIAL SALES ANALYSIS
% Growth
Full Year Full Year
2002 2001 Constant
$m $m Actual Currency
USA 9,351 8,483 10 10
Canada 570 525 9 10
North America 9,921 9,008 10 10
France 1,140 967 18 13
UK 623 759 (18) (20)
Germany 699 682 2 (2)
Italy 765 638 20 16
Sweden 285 263 8 3
Europe others 2,183 1,929 13 8
Total Europe 5,695 5,238 9 5
Japan 977 851 15 21
Rest of World 1,248 1,125 11 15
Total 17,841 16,222 10 9
7 FOURTH QUARTER TERRITORIAL SALES ANALYSIS
% Growth
4th 4th
Quarter Quarter
2002 2001 Constant
$m $m Actual Currency
USA 2,564 2,219 16 16
Canada 147 142 4 5
North America 2,711 2,361 15 15
France 320 266 20 12
UK 147 219 (33) (37)
Germany 196 179 9 2
Italy 214 181 18 10
Sweden 75 64 17 -
Europe others 576 530 9 2
Total Europe 1,528 1,439 6 (1)
Japan 314 260 21 27
Rest of World 348 306 14 19
Total 4,901 4,366 12 10
8 FULL YEAR PRODUCT SALES ANALYSIS
World US
Full Year Full Year Constant Full Year
2002 2001 Actual Currency 2002 Actual
$m $m Growth Growth $m Growth
% % %
Gastrointestinal:
Losec 4,623 5,578 (17) (18) 2,847 (21)
Nexium 1,978 568 n/m n/m 1,525 n/m
Others 63 44 43 38 20 n/m
Total Gastrointestinal 6,664 6,190 8 7 4,392 8
Cardiovascular:
Zestril 877 1,067 (18) (18) 467 (24)
Seloken 901 711 27 27 617 43
Atacand 569 410 39 36 206 37
Plendil 489 463 6 5 209 6
Tenormin 370 404 (8) (7) 52 (2)
Others 363 428 (15) (18) 13 (82)
Total Cardiovascular 3,569 3,483 2 1 1,564 3
Respiratory:
Pulmicort 812 766 6 5 361 35
Rhinocort 299 265 13 13 211 19
Symbicort 299 83 n/m n/m - -
Accolate 144 143 1 2 104 5
Oxis 120 127 (6) (9) - -
Others 144 155 (7) (9) - -
Total Respiratory 1,818 1,539 18 16 676 24
Oncology:
Zoladex 794 718 11 12 212 7
Casodex 644 561 15 15 180 (23)
Nolvadex 480 618 (22) (21) 337 (27)
Arimidex 331 188 76 75 134 127
Iressa 67 - n/m n/m - -
Faslodex 35 - n/m n/m 35 n/m
Others 18 26 (31) (31) - -
Total Oncology 2,369 2,111 12 12 898 (6)
CNS:
Seroquel 1,145 685 67 67 927 67
Zomig 328 273 20 19 177 20
Others 32 22 45 40 7 17
Total CNS 1,505 980 54 53 1,111 57
Pain, Infection and Other
Pharma:
Diprivan 443 456 (3) (3) 216 3
Merrem 285 227 26 26 59 9
Local anaesthetics 432 434 - - 113 (12)
Other Pharma Products 258 379 (32) (31) 75 (32)
Total Pain, Infection and Other
Pharma 1,418 1,496 (5) (5) 463 (8)
Salick Health Care 233 194 20 20 233 20
Astra Tech 151 126 20 14 11 38
Marlow Foods 114 103 11 8 3 -
Total 17,841 16,222 10 9 9,351 10
n/m not meaningful
9 FOURTH QUARTER PRODUCT SALES ANALYSIS
World US
4th 4th Constant 4th
Quarter Quarter Actual Currency Quarter Actual
2002 2001 Growth Growth 2002 Growth
$m $m % % $m %
Gastrointestinal:
Losec 1,115 1,372 (19) (20) 684 (17)
Nexium 686 278 n/m n/m 521 n/m
Others 18 14 29 15 7 n/m
Total Gastrointestinal 1,819 1,664 9 7 1,212 14
Cardiovascular:
Zestril 144 256 (44) (44) 46 (68)
Seloken 263 165 59 60 182 107
Atacand 160 124 29 24 55 15
Plendil 139 136 2 - 63 (6)
Tenormin 95 104 (9) (8) 10 -
Others 93 115 (19) (29) (1) n/m
Total Cardiovascular 894 900 (1) (3) 355 (7)
Respiratory:
Pulmicort 237 203 17 14 120 62
Rhinocort 76 74 3 3 54 2
Symbicort 105 49 n/m n/m - -
Accolate 52 30 73 73 41 128
Oxis 29 33 (12) (18) - -
Others 38 40 (5) (10) - -
Total Respiratory 537 429 25 21 215 48
Oncology:
Zoladex 206 205 - - 55 8
Casodex 184 173 6 5 46 (35)
Nolvadex 138 181 (24) (24) 99 (27)
Arimidex 92 51 78 75 32 167
Iressa 41 - n/m n/m - -
Faslodex 16 - n/m n/m 16 n/m
Others 4 4 - - - n/m
Total Oncology 681 614 11 11 248 (8)
CNS:
Seroquel 357 170 110 109 292 130
Zomig 94 67 40 39 52 63
Others 9 6 50 33 2 100
Total CNS 460 243 89 87 346 116
Pain, Infection and Other
Pharma:
Diprivan 117 133 (12) (13) 58 (13)
Merrem 69 65 6 8 8 (53)
Local anaesthetics 121 102 19 19 37 3
Other Pharma Products 68 104 (35) (33) 18 (36)
Total Pain, Infection and Other
Pharma 375 404 (7) (7) 121 (18)
Salick Health Care 63 50 26 26 63 26
Astra Tech 43 36 19 2 3 -
Marlow Foods 29 26 12 4 1 -
Total 4,901 4,366 12 10 2,564 16
n/m not meaningful
Convenience Translation of Key Financial Information
2001 2001 2001
2002 (restated) 2002 (restated) 2002 (restated)
For the three months ended 31 $m $m £m £m SEKm SEKm
December
Total Sales 4,901 4,366 3,045 2,713 42,982 38,290
Operating profit before
exceptional items (EI) 1,074 1,090 667 677 9,419 9,559
Profit before tax on continuing
operations before EI 1,081 1,102 672 685 9,480 9,665
Net profit for the period 428 726 266 451 3,754 6,367
Earnings per Ordinary Share pre
EI $0.45 $0.45 £0.28 £0.28 SEK3.95 SEK3.95
2001 2001 2001
2002 (restated) 2002 (restated) 2002 (restated)
For the year ended 31 December $m $m £m £m SEKm SEKm
Total Sales 17,841 16,222 11,086 10,080 156,466 142,267
Operating profit before
exceptional items (EI) 4,356 4,156 2,707 2,582 38,202 36,448
Profit before tax on continuing
operations before EI 4,387 4,269 2,726 2,653 38,474 37,439
Net profit for the year 2,836 2,906 1,762 1,806 24,872 25,486
Basic earnings per Ordinary
Share $1.64 $1.65 £1.02 £1.03 SEK14.38 SEK14.47
Earnings per Ordinary Share pre
EI $1.84 $1.73 £1.14 £1.08 SEK16.14 SEK15.17
Dividend per Ordinary Share $0.70 $0.70 43.2p 49.3p SEK6.20 SEK7.45
Net cash inflow from operating
activities 5,593 3,762 3,475 2,338 49,051 32,993
Decrease in cash (22) (396) (14) (246) (193) (3,473)
Shareholders' funds - equity
interests 31 December 11,172 9,586 6,942 5,957 97,978 84,069
Sterling (£) and Swedish Kronor equivalents are shown for convenience and have
been calculated using the current period end rates of $1=£0.621388 and $1=
SEK8.77, respectively. Dividend per Ordinary Share is shown as the actual
amount payable using the rates at the date of declaration of the dividend.
Information for US Investors
RECONCILIATION TO UNITED STATES ACCOUNTING PRINCIPLES
The Group profit and loss account and Group balance sheet set out on pages 9, 10
and 11 are prepared in accordance with generally accepted accounting principles
in the United Kingdom (UK GAAP) which differ in certain material respects from
those generally accepted in the United States (US GAAP). The differences as
they apply to AstraZeneca PLC are explained in the Group's 2001 Annual Report
and Form 20-F except that, in the current year, AstraZeneca adopted SFAS No141 '
Business Combinations' and SFAS No142 'Goodwill and Other Intangible Assets'.
As a result goodwill is no longer amortised but tested annually for impairment.
The effect has been to increase profit by approximately $755m. The approximate
effects on Group income and shareholders' equity of the GAAP differences are
shown below.
2002 2001
Income attributable to Shareholders $m $m
Net income for the year under UK GAAP (2001 restated) 2,836 2,906
Adjustments to conform to US GAAP
Purchase accounting adjustments, (including goodwill and intangibles);
- deemed acquisition of Astra
- amortisation and other acquisition adjustments (864) (1,514)
- others 55 -
Capitalisation, less disposals and amortisation of interest 46 57
Deferred taxation
- on fair value of Astra 239 249
- others (99) (198)
Pension expense (50) (33)
Post-retirement benefits/plan amendment 4 4
Software costs capitalised (46) (10)
Restructuring costs - (22)
Share based compensation 33 (7)
Fair value of derivative financial instruments 93 18
Deferred income recognition 61 (75)
Unrealised losses on foreign exchange and others (1) (10)
Net income before cumulative effect of change in accounting policy 2,307 1,365
Cumulative effect of change in accounting policy, net of tax, on
adoption - 32
of SFAS No. 133
Net income in accordance with US GAAP 2,307 1,397
Net income per Ordinary Share under US GAAP (basic) $1.33 $0.79
Net income per Ordinary Share under US GAAP (diluted) $1.33 $0.79
RECONCILIATION TO UNITED STATES ACCOUNTING PRINCIPLES
31 Dec 31 Dec
2002 2001
Shareholders' equity $m $m
Shareholders' equity under UK GAAP (2001 restated) 11,172 9,586
Adjustment to conform to US GAAP
Purchase accounting adjustments, (including goodwill and intangibles);
- deemed acquisition of Astra
- goodwill 12,692 11,062
- tangible and intangible fixed assets 7,707 8,139
- others 86 31
Capitalisation, less disposals and amortisation of interest 238 192
Deferred taxation
- on fair value of Astra (2,305) (2,313)
- others (159) (68)
Dividend 808 820
Pension expense (271) (162)
Post-retirement benefits/plan amendment (24) (28)
Software costs capitalised 64 110
Fair value of derivative financial instruments 99 50
Deferred income recognition (14) (75)
Others 90 58
Shareholders' equity in accordance with US GAAP 30,183 27,402
Shareholder Information
ANNOUNCEMENTS AND MEETINGS
Announcement of first quarter 2003 results 30 April 2003
Annual General Meeting 2003 30 April 2003
Announcement of second quarter and half year 2003 24 July 2003
results
Annual Business Review 2003 2 October 2003
Announcement of third quarter and nine months 2003 23 October 2003
results
DIVIDENDS
The record date for the first interim dividend paid on 7 October 2002 (in the
UK, Sweden and the US) was 23 August 2002. Ordinary Shares traded ex-dividend
on the London and Stockholm Stock Exchange from 21 August 2002. ADRs traded
ex-dividend on the New York Stock Exchange from the same date.
The record date for the second interim dividend for 2002 payable on 7 April 2003
(in the UK, Sweden and the US) will be 21 February 2003. Ordinary Shares will
trade ex-dividend on the London and Stockholm Stock Exchange from 19 February
2003. ADRs will trade ex-dividend on the New York Stock Exchange from the same
date.
Future dividends will normally be paid as follows:
First interim Announced in July and paid in October
Second interim Announced in January and paid in April.
TRADE MARKS
The following brand names used in this interim report are trade marks of the
AstraZeneca group of companies:
Accolate Arimidex Astra Tech Atacand Atacand HCT Casodex Crestor
Diprivan Exanta Faslodex Iressa Losec Merrem Nexium Nolvadex Oxis
Plendil Prilosec Pulmicort Pulmicort Respules Pulmicort Turbuhaler
Rhinocort Rhinocort Aqua Seloken Seroquel Symbicort Tenormin Toprol-XL
Zestril Zoladex Zomig Zomig ZMT Zomig Rapimelt
ADDRESSES FOR CORRESPONDENCE
Registrar and Depositary Registered Office Swedish Securities Register Centre
Transfer Office for ADRs VPC AB
The AstraZeneca Registrar JPMorgan Chase Bank 15 Stanhope Gate PO Box 7822
Lloyds TSB Registrars PO Box 43013 London S-103 97 Stockholm
The Causeway Providence, W1K 1LN Sweden
Worthing RI 02940-3013 UK
West Sussex US
BN99 6DA
Tel: +44 (0)121 433 8000 Tel: +1 (781) 575 4328 Tel: +44 (0)20 7304 5000 Tel: +46 (0)8 402 9000
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
In order to utilise the 'Safe Harbor' provisions of the United States Private
Securities Litigation Reform Act of 1995, AstraZeneca is providing the following
cautionary statement. This Preliminary Report contains forward-looking
statements with respect to the financial condition, results of operations and
businesses of AstraZeneca. By their nature, forward-looking statements and
forecasts involve risk and uncertainty because they relate to events and depend
on circumstances that will occur in the future. There are a number of factors
that could cause actual results and developments to differ materially from that
expressed or implied by these forward-looking statements. These factors
include, among other things, exchange rate fluctuations, the risk that research
and development will not yield new products that achieve commercial success, the
impact of competition, price controls and price reductions, the risk of loss or
expiration of patents or trade marks, difficulties of obtaining and maintaining
governmental approvals for products, the risk of substantial product liability
claims and exposure to environmental liability.
This information is provided by RNS
The company news service from the London Stock Exchange
Latest directors dealings
- 1 hour ago Zotefoams
- 1 hour ago Antofagasta
- 1 hour ago United Utilities Group
- 2 hours ago Morgan Sindall Group
- 5 hours ago River Global Plc